#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
As cannabis legalization expands across jurisdictions, clinicians need current evidence on cannabis use disorder epidemiology and treatment efficacy to appropriately screen, diagnose, and manage affected patients. The report highlights that legalization has not reduced problematic use patterns and may increase clinical demand, requiring addiction treatment systems to prepare staffing and evidence-based interventions. Understanding these trends allows clinicians to counsel patients on risks, recognize withdrawal syndromes, and refer to appropriate treatment resources rather than dismissing cannabis use as benign.
As cannabis legalization expands across North America, the prevalence of cannabis use disorder (CUD) is rising, yet addiction treatment systems remain unprepared to address this growing clinical need. The Canadian Centre on Substance Use and Addiction reports that current treatment infrastructure lacks sufficient specialized programs, trained clinicians, and evidence-based interventions specifically tailored for CUD, creating a significant gap between demand and available services. Unlike alcohol and opioid use disorders, which have established treatment protocols and funding mechanisms, CUD treatment remains fragmented and underfunded, leaving many patients without access to appropriate care. This disparity is particularly concerning given that CUD affects an estimated 9 percent of cannabis users and may worsen co-occurring psychiatric and substance use conditions if left untreated. Clinicians should recognize that legalization does not reduce addiction risk and should screen for CUD systematically while advocating for integration of evidence-based CUD treatment into existing addiction services. Physicians can improve patient outcomes by becoming familiar with cognitive-behavioral approaches and motivational interviewing for CUD, and by connecting patients to specialized programs where available or working with addiction specialists for guidance.
“What we’re seeing in clinical practice is that legalization has paradoxically increased both access to cannabis and the number of patients presenting with cannabis use disorder, particularly those using high-potency products daily, and our addiction treatment infrastructure simply wasn’t designed to manage this volume or the specific withdrawal syndromes these patients experience.”
💊 As cannabis legalization expands across jurisdictions, clinicians should recognize that legal availability does not eliminate cannabis use disorder (CUD), and may paradoxically increase treatment demand through normalization of use and expanded access to higher-potency products. The Canadian evidence synthesis highlights a critical gap between rising CUD prevalence and treatment system capacity, particularly for adolescents and concurrent polysubstance users where cannabis is often a secondary concern overshadowed by opioid or alcohol dependence. Key confounders include variable THC concentrations across products, individual vulnerability factors (genetic predisposition, neurodevelopmental stage, psychiatric comorbidity), and the heterogeneous quality of existing addiction treatment infrastructure across regions. Clinicians should proactively screen for CUD in routine practice, especially among young adults and those with mental health or substance use histories, while advocating for adequate training and resources to address this growing population within existing addiction services rather than assuming
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: